Eikon Therapeutics announced it will present six abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing progress in its clinical-stage cancer drug programs. The presentations include updated trial data for EIK1001 (targeting lung cancer and melanoma), EIK1003 (a PARP1 inhibitor for various solid tumors), and EIK1005 (a WRN inhibitor for tumors with DNA replication issues). These updates highlight Eikon's efforts to develop novel therapies for advanced cancers, with ongoing studies exploring both monotherapy and combination treatments. The data presentations aim to inform future patient selection and treatment strategies, supporting potential drug registrations.
Ether has surged about 11% over the past week, outperforming other major cryptocurrencies like Bitcoin, which rose 4%. This rise is driven by $96 million inflows into U.S. spot ether ETFs, mainly BlackRock’s low-fee funds, while Grayscale’s higher-fe...
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
